Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce that the Australian Research Council (ARC) has awarded Monash University a grant of A$652,248 over three years under the ARC’s Linkage Projects scheme to support its continuing research collaboration with Immutep into Lymphocyte Activation Gene-3 (LAG-3). The ARC Linkage Projects scheme is highly competitive and supports collaborations between Australian researchers and industry partners that address significant research challenges and deliver benefits to Australia.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.